| Company name | Teva Pharmaceutical Industries Ltd (ADR) |
| Stock ticker | TEVA |
| Live stock price | [stckqut]TEVA[/stckqut] |
| P/E compared to competitors | Good |
MANAGEMENT EXECUTION
| Employee productivity | Good |
| Sales growth | Good |
| EPS growth | Good |
| P/E growth | Good |
| EBIT growth | Fair |
ANALYSIS
| Confident Investor Rating | Good |
| Target stock price (TWCA growth scenario) | $39.04 |
| Target stock price (averages with growth) | $48.75 |
| Target stock price (averages with no growth) | $44.89 |
| Target stock price (manual assumptions) | $38.78 |
The following company description is from Google Finance: http://www.google.com/finance?q=teva
Teva Pharmaceutical Industries Ltd (Teva) is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business provides vertical integration to Teva’s own pharmaceutical production. The Company’s global operations are conducted from North and Latin America to Europe and Asia. As December 31, 2010, it had direct operations in approximately 60 countries, including 40 finished dosage pharmaceutical manufacturing sites in 19 countries, 28 pharmaceutical research and development (R&D) centers and 21 API manufacturing sites. On October 14, 2011, it acquired Cephalon, Inc.
Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor.